The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
21h
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results